(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Pure tirzepatide solutions without B12 appear clear or slightly opalescent
While oral supplements may be effective for some, the bodys ability to absorb them often decreases with age
Each vial also contains Sodium Chloride, 0.9%
A deficiency can occur for several reasons, such as pernicious anemia (a condition where the body cannot absorb vitamin B12 from the diet), certain medical conditions (e.g., Crohn's disease, celiac disease), surgical removal of part of the stomach or intestine, or strict vegetarian/vegan diets if not adequately supplemented
However, people with low energy or less mobility may benefit more from larger MIC b12 doses
